Loading
Life sciences · Journal article
Discover Oncology · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Despite the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib in EGFR -mutant non-small cell lung cancer (NSCLC) patients, a subset of drug-tolerant persister (DTP) cells remains. While protein alterations unique to DTPs are crucial for their survival, the mechanisms remain unclear. Vitamin C has been proposed as an adjunct therapy, but its selective effects on DTPs and underlying anti-cancer mechanisms require further clarification. This study explored whether vitamin C co-treatment could selectively eliminate DTPs by targeting DTP-associated proteins. Proteomic profiling using mass spectrometry identified key molecular changes, from which candidate proteins sensitive to vitamin C were selected. Clinical data were also analyzed to link these proteins to survival outcomes in NSCLC patients. Co-treatment with vitamin C and erlotinib selectively suppressed DTP survival by suppressing CERK and KRT82. CERK was linked to DTP survival through AKT phosphorylation, while KRT82 was associated with changes in epithelial-mesenchymal transition (EMT) phenotype. Clinically, high keratin filament expression correlated with poorer prognosis in patients with EGFR -mutant NSCLC. Overall, our findings demonstrate that vitamin C effectively inhibits the survival of EGFR -mutant NSCLC cells by targeting CERK and KRT82, supporting its use as a safe and effective combination strategy to eliminate TKI-induced DTPs in NSCLC.